Pharmaceuticals News and Research

RSS

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that its Phase 3 pivotal study of GATTEX met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome.

31 Jan 2011

Alexion announces acquisition of Taligen Therapeutics

Alexion Pharmaceuticals, announced that it has acquired Taligen Therapeutics, a privately held development-stage biotechnology company based in Cambridge, Mass.

31 Jan 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Jiangsu Aosaikang Pharmaceutical to take 5% equity position in Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, today announced that a binding subscription agreement has been executed in relation to share placement with Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“ASK”). The proposed placement is for the issue of 14,334,080 LCT shares at A$0.12 per share, to raise A$1.72m. This represents a 5% equity stake in LCT, the funds to be received by LCT from ASK not later than 4 March 2011.

31 Jan 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

Endo Pharmaceutical partners receive Paragraph IV Certification for generic version of LIDODERM

Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, have received a Paragraph IV Certification Notice from Mylan Technologies advising of the filing of an Abbreviated New Drug Application for a generic version of LIDODERM.

31 Jan 2011

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Retired San Francisco real estate developer Douglas Rosenberg says he has a new job - helping to find a cure for Alzheimer's disease. Through the Ellen and Douglas Rosenberg Foundation, the venture philanthropist is betting at least $3.5 million that Buck faculty Dale Bredesen, MD has the correct take on how to thwart the memory robbing disease that affects over 5 million Americans.

31 Jan 2011

Caraco generates $40.4 million and $268.2 million in third quarter, first nine months of Fiscal Year 2011

Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $40.4 million and $268.2 million in the third quarter and first nine months of its Fiscal Year 2011, respectively, as compared to $52.0 million and $178.4 million, respectively, for the corresponding periods of our previous fiscal year ended December 31, 2009.

30 Jan 2011

Best Practices report: 50% of participating companies fail collect AE reports from Internet sources

Drug safety remains front and center for the U.S. Food and Drug Administration as the agency strives to improve the public's perception of the organization. Likewise, the pharmaceutical industry is focused on improving its reputation among consumers and recognizes that its diligence in the reporting of adverse events plays an important role in that effort.

29 Jan 2011

Angiotech commences CCAA proceedings to implement pre-packaged financial restructuring

Angiotech Pharmaceuticals, Inc. today announced that, further to its news release issued earlier today, the Company and certain of its subsidiaries have voluntarily commenced proceedings under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction, having obtained an Initial Order from the Supreme Court of British Columbia today.

29 Jan 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

Angiotech to continue implementation of previously announced recapitalization transaction under CCAA

Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.

29 Jan 2011

Bionovo prices public offering of common stock at $1.30 per share

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the pricing of its previously announced underwritten public offering, to sell up to 30,031,200 units at a price per unit of $1.00 for aggregate gross proceeds of approximately $30 million.

29 Jan 2011

Adeona to sell 2.85 million common stock at $1.40 per share

Adeona Pharmaceuticals, a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement for the sale of approximately 2.85 million shares of its common stock at $1.40 per share to two new institutional investors in a registered direct offering for $4 million in gross proceeds.

29 Jan 2011

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

Ben-Gurion University of the Negev and the PTT Chemical Public Company Ltd. in Thailand have signed a research and development collaboration agreement for commercial development of BGU's proprietary green algae strain.

29 Jan 2011

HBA to honor Pfizer chief medical officer as its 2011 Woman of the Year

The Healthcare Businesswomen's Association announced that its 2011 "Woman of the Year" is Freda Lewis-Hall, MD, chief medical officer of Pfizer. In her distinguished 30-year career, Dr. Lewis-Hall has held leadership roles in direct patient care, academics, media, government, pharmaceuticals and biotechnology.

29 Jan 2011

King Pharmaceuticals awards payment to Pain Therapeutics for abuse-resistant medications

Pain Therapeutics, today announced that it had received a $5,000,000 milestone payment from King Pharmaceuticals, its exclusive commercial partner for abuse-resistant prescription pain medications.

29 Jan 2011

FDA approves Mylan's ANDA for ER Tablets

Mylan today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Nisoldipine Extended-release Tablets, 8.5 mg, 17 mg, 25.5 mg and 34 mg.

29 Jan 2011

Recent releases in Global Health

Innovative Health Financing Can Benefit Global Health, Pharma: "The launch of pneumococcal vaccination in Nicaragua under AMC [advance market commitment] has shown that innovative approaches to health financing can benefit both global health and pharmaceutical companies," according to a Lancet Infectious Diseases editorial that describes how the roll-out of GAVI initiative is helping to provide developing countries with low-cost pneumococcal vaccines.

28 Jan 2011

Pharmaceuticals News and Research

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

Alexion announces acquisition of Taligen Therapeutics

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Jiangsu Aosaikang Pharmaceutical to take 5% equity position in Living Cell Technologies

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Extreme morning sickness drug comes at a price

Endo Pharmaceutical partners receive Paragraph IV Certification for generic version of LIDODERM

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Caraco generates $40.4 million and $268.2 million in third quarter, first nine months of Fiscal Year 2011

Best Practices report: 50% of participating companies fail collect AE reports from Internet sources

Angiotech commences CCAA proceedings to implement pre-packaged financial restructuring

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Angiotech to continue implementation of previously announced recapitalization transaction under CCAA

Bionovo prices public offering of common stock at $1.30 per share

Adeona to sell 2.85 million common stock at $1.40 per share

BGU, PTT sign R&D collaboration agreement for commercial development of green algae strain

HBA to honor Pfizer chief medical officer as its 2011 Woman of the Year

King Pharmaceuticals awards payment to Pain Therapeutics for abuse-resistant medications

FDA approves Mylan's ANDA for ER Tablets

Recent releases in Global Health

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence